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Abstract
Background: Despite intensive multimodal treatment, outcome of patients with malignant glioma
remains poor, and a standard dose of radiotherapy for anaplastic astrocytoma has not been defined.
In the past RTOG study (83-02), the arm of 72 Gy hyperfractionated radiotherapy (HFRT) for
malignant gliomas showed better outcome than the arms of higher doses (76.8 – 81.6 Gy) and the
arms of lower doses (48 – 54.4 Gy). The purpose of this study is to verify the efficacy of this
protocol.
Methods: From July 1995, 44 consecutive eligible patients with histologically proven anaplastic
astrocytoma were enrolled in this study (HFRT group). The standard regimen in this protocol was
post-operative radiotherapy of 72 Gy in 60 fractions (1.2 Gy/fraction, 2 fractions/day) with
concurrent chemotherapy (weekly ACNU). The primary endpoint was local control rate (LCR),
and the secondary endpoints were overall survival (OS), progression-free survival (PFS) and late
toxicity.
Results: Three-year OS of the HFRT group was 64.8% (95% confidence interval; 48.4–81.3%).
Three-year PFS rate and LCR were 64.4% (95%CI: 48.4–80.3%) and 81.6% (95%CI: 69.2–94.8%),
respectively.
The number of failures at 5 years in the HFRT group were 14 (32%). The number of failures inside
the irradiation field was only about half (50%) of all failures. One (2%) of the patients clinically
diagnosed as brain necrosis due to radiation therapy.
Conclusion: The results of this study suggested that 72 Gy HFRT seemed to show favorable
outcome for patients with anaplastic astrocytoma with tolerable toxicity.
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Background
Despite the availability of combined multimodality treat-
ment, anaplastic astrocytoma (AA) has an unfavorable
prognosis. Although radical surgery and radiation therapy
have been performed, loco-regional controllability has
not been improved. It has been reported that the median
survival period of patients with AA is 20 – 40 months
(approximately 30 months on average) [1-5]. The major
prognostic factors have been reported to be age, Karnofsky
performance status and site of lesion, and the minor prog-
nostic factors have been reported to be extent of surgery,
total radiation dose, Ki67 labeling index, and various
other factors [1-9].
In radiation therapy, dose escalation by conventional frac-
tionation has been unsuccessful, and studies on dose esca-
lation by hyperfractionated or accelerated
hyperfractionated radiation therapy have been performed
[1,10]. No significant difference was found between sur-
vival in the low-dose group (60 – 72 Gy) and survival in
the high-dose group (74 – 82 Gy), but results suggested
that 72 Gy was the best dose for good prognosis. Based on
results of those studies, we planned a single-arm study of
72 Gy hyperfractionated radiation therapy limited to
patients with grade 3 glioma.
The primary objective of this study was to evaluate the
efficacy of 72 Gy hyperfractionated radiation therapy in
terms of overall survival, progression-free survival and
loco-regional control rate for patients with AA. The sec-
ondary objective was to evaluate the toxicity and feasibil-
ity of this treatment.
Methods
Patients
Since July 1995, patients with histologically proven grade
3 glioma (anaplastic astrocytoma) have been treated in
our institution by 72 Gy hyperfractionated radiation ther-
apy (HFRT) with surgery and chemotherapy. Histological
diagnosis was determined on the basis of the 2nd edition
of WHO (World Health Organization) classification of
brain tumors.
The main points of eligibility criteria of this study were 1)
histopathologically proven anaplastic astrocytoma, 2) pri-
mary lesion arising from the central nervous system
(except brain stem and spinal cord), 3) feasibility of com-
pletion of a course of treatment, and 4) written informed
consent for surgery and verbal informed consent for radi-
otherapy and chemotherapy having been obtained. The
treatment protocol has been inspected and validity of
treatment has been approved by the Institutional Ethics
Committee of Tohoku University School of Medicine.
All patients with anaplastic astrocytoma who met the
above criteria were enrolled in this study. Patients with
other grade 3 gliomas (anaplastic oligoastrocytoma, ana-
plastic oligodendroglioma, etc.) were excluded in order to
exclude histopathological bias and influence on clinical
outcome. Patients with grade 3 glioma arising from the
brain stem or spinal cord were excluded from this study
because of intolerability for high-dose radiation therapy.
Patients with diffusely extended gliomatosis cerebri
requiring nearly whole brain irradiation were also
excluded because of intolerability for high-dose whole
brain irradiation. Patients who appeared to be in
extremely poor condition (Karnofsky score ≤ 30, indica-
tion of emergency operation, and definitely unable to
complete a course of treatment) were excluded from this
study. Informed consent for the treatment was obtained
from all enrolled patients.
Performance status (PS) was determined according to the
criteria of Karnofsky score before treatment. Tumor size
was measured as the length of the long axis of the tumor
by more than one diagnostic radiologist using images of
enhanced-computed tomography (CT) and/or T2-
weighted (T2WI) or enhanced T1-weighted (T1WI) mag-
netic resonance (MR) imaging.
Radiation therapy
HFRT group: All patients were irradiated with 6–10 mega-
volt photons by a linear accelerator, and all patients were
immobilized by a resinous shell during irradiation.
Patients were irradiated with an extended local field dur-
ing treatment, and none of the patients underwent whole
brain irradiation. The extended local irradiation field
included the whole T2WI high-intensity region on MR
images or a 2–3-cm margin around the tumor or tumor
bed, and more than 2 fields were used. The standard
schedule of irradiation was 72 Gy/60 fractions/6 weeks
(1.2 Gy/fraction, and 2 fractions in a day with an interval
of at least 6 hours).
Biologically equivalent dose (BED) was calculated on the
basis of the Linear-Quadratic model (a). According to pre-
viously reported experimental data, the alpha/beta value
of grade 3 gliomas was assumed to be 14 Gy [11-13].
BED (Dx) = [(alpha/beta + dx)/(alpha/beta + dr)] × Dr ---
(a)
(Dr = total reference dose, dr = single reference dose/frac-
tion, Dx = BED of altered fractionation, dx = altered single
dose/fraction.)
Other treatments
The extent of surgery was evaluated by postoperative MR
imaging within 72 hours after surgery (All patients haveBMC Cancer 2008, 8:11 http://www.biomedcentral.com/1471-2407/8/11
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routinely been examined by MR imaging.). If the tumor
was enhanced on preoperative MR images, gross total
resection of the tumor was defined as resection with no
residual enhanced tumor, subtotal resection was as
defined as more than 75% resection, and partial resection
was as defined as less than 75% resection. If the tumor was
not enhanced on preoperative MR images, resection was
evaluated on the basis of resection of the high-intensity
lesion on T2-weighted MR images. Surgery (or biopsy)
was performed before radiation therapy, and chemother-
apy was performed concomitantly. The main drug used in
chemotherapy was nimustine hydrochloride (ACNU).
Patients were given 2–3 weekly courses of 2–3 mg/kg
ACNU (single injection per week). The dose of chemo-
therapy was determined according to patient's age, renal
function and general condition.
Toxicity
Toxicity was clinically diagnosed on the basis of CTC
(common toxicity criteria) version 2.0. Patients who
showed severe adverse events (≥ grade 3 leukoencepha-
lopathy-associated radiological findings, brain necrosis
diagnosed by CT, MR imaging and/or histopathologic
findings) were regarded as having late toxicity. After a
course of treatment, follow-up CT or MRI was performed
once in 1 to 4 months. If a new enhanced region appeared
in the follow-up examination but improved with no treat-
ment during the observation period, it was regarded as
post-operative change or no recurrence. If a new enhanced
region or tumorous lesion appeared and there were defi-
nite findings of progression, it was regarded as a failure
case. If it was difficult to distinguish failure from brain
necrosis, biopsy was performed and histopathological
proof was obtained.
Statistical analysis
Survival period was calculated from the first date of treat-
ment, and the final follow-up date was October 1, 2004.
Survival curves were analyzed by the Kaplan-Meier
method and the logrank test. Overall survival was calcu-
lated as the period to the date of death, progression-free
survival was calculated as the period to the date of the first
progression (loco-regional failure and/or distant failure),
and local control survival was calculated as the period to
the date of the first loco-regional progression (distant
metastasis and dissemination outside the irradiation field
not included).
Results
From July 1995 to August 2004, 56 patients were initially
diagnosed as having anaplastic astrocytoma. It took 9
years to enroll a sufficient number of patients, but the
number of patients per year approximately corresponds to
the calculated incidence [incidence of AA in our area = 6/
year; 12/100,000 (a) × 0.28 (b) × 0.18 (c) × 1,000,000 (d)
= 6 (a: incidence of brain tumor in Japan, b: rate of glioma
in all brain tumors, c: rate of AA in all gliomas, d: popula-
tion of the area; the Ministry of Health and Welfare, Japan,
1998)]. Three (5.3%) of 56 patients were excluded from
this trial because of intolerability of normal tissue (tumor
located at basal ganglia or gliomatosis cerebri). One
patient (1.7%) was histologically reviewed and classified
into glioblastoma multiforme. Eight (14.3%) of 56
patients were excluded because informed consent could
not be obtained or they chose other treatment protocols.
A total of 44 eligible patients with histologically proven
anaplastic astrocytoma underwent 72 Gy hyperfraction-
ated radiation therapy. All patients completed the sched-
uled irradiation. The median follow-up period of survival
patients was 35.1 months. Characteristics of the patients
are shown in Table 1.
Figure 1 shows the overall survival curve of the 44
patients. Three-year overall survival rate of the HFRT
group was 64.8% (95% confidence interval: 48.4–81.3%)
and 5-year overall survival rate was 60.9% (95%CI: 43.6 –
71.2%). Three-year and 5-year PFS rates were 64.4%
(95%CI: 48.4% – 80.3%) and 53.7% (95% CI: 30.4 –
77.1%), respectively (Figure 2). Three-year and 5-year
LCRs were 81.6% (69.2 – 94.8%: 95%CI) and 81.6%
(95%CI: 69.2–94.8%), respectively (Figure 3).
Table 1: Patients' characteristics
Number of patients 44
Age (mean ± S.D.) 39.8 ± 17.3
Gender Male 30
Female 14
Karnofsky score 
(performance status)
80–100 27 (61%)
60–70 15 (34%)
40–50 2 (5%)
0–30 0
Site of lesion Frontal lobe 23 (52%)
Temporal lobe 9 (21%)
Parietal lobe 3 (7%)
Others 9 (21%)
Tumor size (cm) median (range) 5 cm (1–11)
Extent of surgery Total/Subtotal resection 23 (52%)
Partial resection/Biopsy only 21 (48%)
BED (Gy) (mean ± S.D.) 68.5 ± 0.36
Chemotherapy with 36 (82%)
without 8 (18%)BMC Cancer 2008, 8:11 http://www.biomedcentral.com/1471-2407/8/11
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Patterns of failure are shown in Table 2. The number of
failures at 5 years in the HFRT group was 14 (32%). The
number of failures inside the irradiation field was only
about half (7/14: 50%) of all failures. On the other hand,
the ratio of failures outside the irradiation field was higher
(10/14: 71%) than those inside field. Nine (90%) of the
10 cases of failure outside the irradiation field were
cerebrospinal dissemination that was diagnosed by
enhanced-CT/MRI. The other patient showed diffuse infil-
tration like gliomatosis cerebri.
All 44 patients completed the scheduled irradiation (72
Gy/60 fr./6 weeks) and 39 (89%) of the 44 patients com-
pleted radiation therapy within a 4-day prolongation
(including holidays). Five patients (11%) took more than
4-day prolongation in radiation therapy. In 4 of those 5
patients, radiation therapy was suspended due to tran-
sient brain edema caused by irradiation or post-operative
changes. However, their condition was improved by anti-
edema therapy and radiation therapy was restarted as
soon as possible. One patient had progression completely
outside the irradiation field (contralateral brain) during
the radiation therapy. This lesion was not detected in the
pre-treatment examinations, so the lesion was diagnosed
by biopsy and the radiation therapy was suspended dur-
ing the examination. Finally, this patient was diagnosed as
having progression in the course of treatment, but, this
patient was included in the analysis due to the initial con-
dition and completion of treatment. This patient was cen-
sored as a case of failure outside the irradiation field.
Overall survival rates of the HFRT group Figure 1
Overall survival rates of the HFRT group. Three-year and 
5-year overall survival rates were 64.8% and 60.8%, 
respectively.
Progression-free survival rates of the HFRT group Figure 2
Progression-free survival rates of the HFRT group. Three-
year and 5-year PFS rates were 64.4% and 53.7%, 
respectively.
Local control rate of the HFRT group Figure 3
Local control rate of the HFRT group. Three-year and 5-year 
LCRs were 81.6% and 81.6%, respectively.
Table 2: Patterns of failure and severe late toxicity
Total failure 14/44 (32%)
Failure inside field 7/14 (50%)
Failure outside field 10/14 (71%) (CSF dissemination: 
9, contralateral brain: 1)
Severe late toxicity
Brain necrosis 1 (2%)BMC Cancer 2008, 8:11 http://www.biomedcentral.com/1471-2407/8/11
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There were no other cases of suspension of radiation ther-
apy due to acute toxicity > grade 3.
Six (14%) of the 44 patients were not given chemotherapy
due to their age (> 60 years). Two patients (5%) were not
so old but they were not given chemotherapy because of
their poor general condition. Thirty-six patients (82%)
were given at least 2 courses of weekly ACNU infusion.
One (2%) of the patients in the HFRT group showed
severe late toxicity clinically diagnosed as brain necrosis
due to radiation therapy. This patient had undergone
intra-thecal injection of MTX (Due to residual tumor and
possibility of dissemination, MTX was used only in this
case.). Radiographical change appeared 3 months after
radiation therapy, and the patient died of cerebral infarc-
tion 30 months after the radiographical change had
appeared. No definite relationship between death and late
toxicity was found, and the case was therefore considered
to be non-cancer-related and non-treatment-related
death. Two patients showed mild changes in radiographi-
cal findings with no symptoms. It was not determined
whether the changes were local failure or brain necrosis,
and the patients are now being observed with no treat-
ment at the date of final follow-up. Other patients showed
no significant changes in clinical symptoms after irradia-
tion.
Discussion
Werner-Wasik et al. analyzed cases of 130 AA in an RTOG
83-02 trial and they reported that the median survival
time (MST) of patients with AA was 40.3 months [1]. In
the RTOG 83-02 trial, it was found that the MSTs of the
48–54.4 Gy, 64.8–72 Gy and 76.8–81.6 Gy groups were
35–40.6, 50–85.8 and 30.4–35.4 months, respectively.
These results showed that a very small dose and a very
large dose of radiation therapy did not lead to a favorable
prognosis. The 64.8 Gy group showed a very long MST
(85.8 months), but this group consisted of only 9 patients
and data are therefore not sufficient.
Tortosa et al. analyzed 95 cases of anaplastic glioma retro-
spectively, and MST of the patients was 29 months [2].
The median age of the patients was 49 years, the propor-
tion of patients with KPS ≥ 80 was 60%, total resection
rate was 35% and standard dose of external beam radia-
tion therapy (EBRT) was 60 Gy/30 fr. According to known
prognostic factors, the advance age of patients and lower
total resection rate in this trial are thought to be the rea-
sons for the short MST.
Levin et al. analyzed 90 cases of anaplastic glioma (includ-
ing 69 cases of AA) in their phase II study of accelerated
hyperfractionated radiation therapy with chemotherapy,
and the results showed that the MST of patients with AA
was 27.8 months [3]. The patients' characteristics in that
study were not so poor (median age: 37 years, proportion
of patients with KPS ≥ 90: 77%, total or subtotal resection
rate: 77%). However, the EBRT is schedule was irregular
(60 Gy/t.i.d. with 2-week intervals) and the irradiated
dose did not reach 60 Gy (55–57 Gy: 54.4%) in more
than half of the patients. The insufficient dose of EBRT
might be one of the reasons for the relatively poor out-
come. Jeremic et al. analyzed 12 cases of AA and Urtasun
et al. analyzed 21 cases of AA, and the MSTs of the patients
in their studies were 42 months and 38 months, respec-
tively [14,15]. However, both of those studies have a
small impact due to the small number of patients.
Prados et al. analyzed 110 cases of anaplastic glioma
(including 107 cases of AA) and they reported that the 2-
year and 5-year survival were 80% and 66%, respectively
[16]. The characteristics of patients in their trial were favo-
rable (median age: 37 years, total and subtotal resection
rate: 72%, median KPS: 90, EBRT: 60 Gy/30 fr., with
chemotherapy). Although the KPS and the extent of sur-
gery those are known as significant prognostic factors are
better than those of the present study, the outcome of the
present study is almost similar to that of their study. One
of the reasons that the outcome of the present study is
almost equal to that by Prados et al. despite the disadvan-
tage in patients' characteristics might be due to benefits
from fractionation and total dose of radiation therapy.
The dose of EBRT in that trial was less than that in the
present study (60 Gy/30 fr. vs. 72 Gy/60 fr.). On the basis
of the outcomes of above-mentioned reports, it is sug-
gested that not only extent of surgery but also radiation
dose has influence on patients' prognosis. EBRT of 60 Gy
seems to be a necessary dose to control AA. The results of
above-mentioned reports including RTOG study suggests
that the outcome of the patients who underwent radio-
therapy with a total dose of less than 60 Gy of EBRT seems
to be poorer than that of the patients who underwent radi-
otherapy with a total dose of ≥ 60 Gy. However, in con-
ventional fractionation (2 Gy/fr.), the risk of brain
necrosis much increases when total radiation dose exceed
60 Gy. One of the merits is that HFRT can deliver more
total dose with low risk of adverse effect (e.g. brain necro-
sis) than conventional fractionation.
The major pattern of failure in past studies was loco-
regional failure, and it has generally been considered that
the controllability of malignant glioma was extremely
poor in spite of multimodal treatments [17-19]. In those
studies, rates of loco-regional failure were about 80–90%
of all failures. In the present study, 5-year local control
rate is 81.6% (local failure at 5 years is 18.4%). It is
thought that local controllability of AA is getting
improved due to advances in resectability and improve-
ment of radiation dose and fractionation.BMC Cancer 2008, 8:11 http://www.biomedcentral.com/1471-2407/8/11
Page 6 of 7
(page number not for citation purposes)
The average BED of external beam radiation therapy in the
HFRT group was 68.5 Gy. It seemed that the higher total
dose of radiation therapy contributed to loco-regional
controllability. From the viewpoint of radiosensitivity, the
alpha/beta value of malignant glioma tends to be larger
than that of low grade glioma, and it therefore seems to be
possible to deliver high-dose irradiation to the tumor bed
with a localized irradiation field by a hyperfractionated
regimen and to be possible to reduce toxicity of normal
tissue by decreasing single-dose/fraction. The results of
the present study suggested that high dosage of irradiation
is one of the factors enabling control of grade 3 gliomas.
Although there has been a trial using higher single-dose/
fraction, higher single-dose/fraction does not seem to be
very effective from the viewpoint of alpha/beta values of
tumor tissue and normal central nervous tissue [11-13].
The rate of severe late toxicity in this trial was not so high
and seemed to be tolerable (Table 2). One of the patients
who was diagnosed as having brain necrosis was alive at
the last follow-up examination, and the other patient,
who died of cerebral infarction, survived for about 30
months after the appearance of toxicity. Up to the time of
the last follow-up examination, there was no treatment-
related death in this trial. Excessive irradiation and combi-
nation of high-dose MTX injection seem to induce brain
necrosis [20]. Combination of MTX injection with radia-
tion therapy should therefore be carefully determined.
A new problem is failure outside the irradiation field. The
rate of failure outside the field was relatively high in this
trial. One possible reason for this is the low rate of loco-
regional failure and the large number of long-term survi-
vors. It seems that some of the objectives such as improve-
ment of local controllability and improvement of survival
were accomplished by high-dose irradiation to a localized
field. If whole brain irradiation is combined, the rate of
dissemination outside the local field may decrease, but
the risk of toxicity will also increase.
Conclusion
The results of this study suggested that 72 Gy HFRT
seemed to show favorable outcome for patients with ana-
plastic astrocytoma with tolerable toxicity. Further study
is needed to determine whether whole brain irradiation is
necessary and what dose is optimal.
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